A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

Exclusion Criteria

• •Laboratory and medical examination
• •Aspartate Aminotransferase (AST) and / or Alanine Aminotransferase (ALT) \>3.0 x upper limit of normal (ULN) at Visit 1, or moderate or severe liver disease (defined by Child-Pugh score B or C hepatic impairment).
• •Estimated glomerular filtration rate (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula \< 30 mL/min at Visit 1.
• •An absolute blood neutrophil count \<1,000/mm\^3 at Visit 1 (equivalent to \<1,000 cells/µL or \<109 cells/L).
• •Any findings in the medical examination and/or laboratory value assessed at Screening Visit 1 or during screening period, that in the opinion of the investigator may put the patient at risk by participating in the trial.
• •Positive serological tests for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection, or known infection status.
• •Concomitant diagnosis and therapy
• •A current diagnosis of:
• •* Cystic Fibrosis
• •* Hypogammaglobulinemia
• •* Common variable immunodeficiency
• •* α1-antitrypsin deficiency being treated with augmentation therapy
• •* Allergic bronchopulmonary aspergillosis being treated or requiring treatment
• •* Tuberculosis or non-tuberculous mycobacterial infection being treated or requiring treatment according to local guidelines
• •* Palmoplantar keratosis; or keratoderma climactericum
• •* Hypothyroidism, myxedema, chronic lymphedema with associated hyperkeratosis of the skin, acrocyanosis. If a subject has hypothyroidism but is treated and compensated, the subject is allowed into the trial
• •* Psoriasis affecting palms and soles; or body surface area for psoriasis ≥ 10%
• •* Reactive arthritis (Reiter's syndrome); keratoderma blennorrhagicum
• •* Pityriasis rubra pilaris
• •* Atopic dermatitis affecting palms and soles; or body surface area for atopic dermatitis ≥ 10%
• •* Active extensive verruca vulgaris, as per investigator's discretion
• •* Active fungal infection of hand and/or feet not adequately treated, or not responsive to antifungal therapy, as per investigator's discretion.
• •Any clinically relevant (at the discretion of the investigator) acute respiratory infection within 4 weeks prior Visit 2, or any other acute infection requiring systemic or inhaled anti-infective therapy within 4 weeks prior Visit 2.
• •Any evidence of a concomitant disease, such as Papillon-Lefevre Syndrome, relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal disorders, or patients who are immunocompromised with a higher risk of invasive pneumococcal disease or other invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis), that in the opinion of the investigator, may put the patient at risk by participating in the study.
• •Received any live attenuated vaccine within 4 weeks prior to Visit 2.
• •Medical conditions associated with periodontal disease (to be evaluated by a periodontist or dentist):
• •* Any tooth that can potentially cause pain or infection as noted in the oral exam unless they are corrected before the study (e.g. pulp necrosis).
• •* Severe periodontal disease defined as with pocket depth measurements ≥ 6 mm on 2 or more teeth.
• •* Class-3 mobility or Class-3 furcation involvement.
• •* Scheduled tooth extraction during the study period.
• •Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.